🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 12 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 25/10/2016 | 78,88 | 79,75 | 77,43 | 78,71 | -0,03% | 2,94% | 2.557.700 |
| 24/10/2016 | 80,00 | 80,40 | 77,90 | 78,73 | -2,51% | 3,13% | 2.032.700 |
| 21/10/2016 | 82,34 | 82,60 | 80,69 | 80,76 | -2,60% | 2,32% | 1.142.900 |
| 20/10/2016 | 81,40 | 83,26 | 81,40 | 82,92 | +1,33% | 2,29% | 1.045.900 |
| 19/10/2016 | 82,79 | 82,89 | 81,21 | 81,83 | -1,36% | 2,03% | 1.318.800 |
| 18/10/2016 | 81,73 | 83,14 | 81,73 | 82,96 | +3,06% | 1,73% | 1.510.200 |
| 17/10/2016 | 79,36 | 81,54 | 78,50 | 80,50 | +1,60% | 3,83% | 1.934.600 |
| 14/10/2016 | 81,13 | 82,23 | 79,20 | 79,23 | -1,65% | 3,73% | 1.977.000 |
| 13/10/2016 | 79,55 | 81,56 | 79,52 | 80,56 | +0,51% | 2,56% | 2.114.100 |
| 12/10/2016 | 81,81 | 82,82 | 80,04 | 80,15 | -1,85% | 3,40% | 2.255.400 |
| 11/10/2016 | 85,15 | 86,08 | 80,78 | 81,66 | -5,02% | 6,22% | 2.329.300 |
| 10/10/2016 | 86,35 | 86,95 | 85,83 | 85,98 | +0,33% | 1,30% | 799.800 |
| 07/10/2016 | 85,36 | 85,95 | 84,23 | 85,70 | +0,87% | 2,01% | 983.300 |
| 06/10/2016 | 86,74 | 86,88 | 84,88 | 84,96 | -3,07% | 2,31% | 1.375.000 |
| 05/10/2016 | 86,85 | 88,24 | 86,09 | 87,65 | +1,42% | 2,48% | 964.400 |
| 04/10/2016 | 86,94 | 87,25 | 85,75 | 86,42 | -0,43% | 1,73% | 1.081.100 |
| 03/10/2016 | 86,46 | 87,48 | 84,62 | 86,79 | -0,48% | 3,31% | 1.371.300 |
| 30/09/2016 | 85,25 | 88,91 | 83,50 | 87,21 | +2,60% | 6,35% | 2.545.700 |
| 29/09/2016 | 88,45 | 90,77 | 84,99 | 85,00 | -4,32% | 6,53% | 2.381.100 |
| 28/09/2016 | 90,51 | 90,73 | 86,87 | 88,84 | -0,31% | 4,26% | 1.715.000 |
| 27/09/2016 | 88,23 | 89,19 | 87,25 | 89,12 | +0,94% | 2,20% | 1.520.300 |
| 26/09/2016 | 90,05 | 91,23 | 88,10 | 88,29 | -2,58% | 3,48% | 1.608.100 |
| 23/09/2016 | 92,27 | 92,96 | 90,27 | 90,63 | -1,62% | 2,92% | 1.222.200 |
| 22/09/2016 | 92,83 | 93,35 | 90,01 | 92,12 | +0,33% | 3,60% | 1.191.800 |
| 21/09/2016 | 91,99 | 92,71 | 89,08 | 91,82 | +0,14% | 3,95% | 1.936.800 |
| 20/09/2016 | 92,07 | 92,52 | 90,98 | 91,69 | +0,47% | 1,67% | 934.800 |
| 19/09/2016 | 93,21 | 93,59 | 91,09 | 91,26 | -1,56% | 2,68% | 1.183.200 |
| 16/09/2016 | 92,90 | 93,13 | 90,67 | 92,71 | -0,42% | 2,65% | 2.130.300 |
| 15/09/2016 | 90,60 | 94,43 | 89,35 | 93,10 | +3,31% | 5,61% | 2.569.300 |
| 14/09/2016 | 95,02 | 97,77 | 88,16 | 90,12 | -5,41% | 10,11% | 4.992.600 |